Form D · Biotechnology
Irazu Oncology, LLC
Baltimore, MD · CIK 0002004491
Offering snapshot reported Dec 14, 2023 · SEC filing
- Reported sold
- $2.6M Offering amount: $3.9M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 27, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 14, 2023 | Initial | $2,601,180 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-499692
Source: Form D, filed Dec 14, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Berens | Executive |
| Richard Kohr | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
801 W. Baltimore Street Suite 518
Baltimore, MD, 21201
Baltimore, MD, 21201